Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial

Nivolumab is a human monoclonal antibody against the immune checkpoint receptor programmed death‐1, inhibiting binding to programmed death‐ligand 1 or 2 (PD‐L1 or PD‐L2). This phase 2 study evaluated the efficacy and safety of nivolumab in patients with advanced/recurrent uterine cervical cancer, ut...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Kenji, Hasegawa, Kosei, Katsumata, Noriyuki, Matsumoto, Koji, Mukai, Hirofumi, Takahashi, Shunji, Nomura, Hiroyuki, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726684/
https://www.ncbi.nlm.nih.gov/pubmed/31348579
http://dx.doi.org/10.1111/cas.14148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726684/
https://www.ncbi.nlm.nih.gov/pubmed/31348579
http://dx.doi.org/10.1111/cas.14148

Ejemplares similares